Trial Profile
A prospective study to evaluate the short-term outcomes of chemoradiotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 May 2016 New trial record